Gensignia

Gensignia is a privately held molecular diagnostics company headquartered in San Diego, California. With a team of five employees, the company has generated $20 million in revenue. Gensignia specializes in the development and implementation of microRNA signatures as diagnostic tools for various medical applications. The company's primary focus is the creation of proprietary blood-based oncology tests designed to detect cancer at earlier stages with enhanced accuracy. Gensignia aims to offer these specialized tests through its own clinical laboratory (CLIA) beginning in 2015. Their initial target is the detection of lung cancer using a minimally invasive blood test that identifies a specific pattern of microRNAs. Gensignia distinguishes itself through its proprietary intellectual property related to the detection of lung cancer using microRNA signatures in blood samples. This innovative approach offers a potentially less invasive and earlier detection method compared to traditional diagnostic techniques. For more information about Gensignia and its services, please visit their website at gensignia.com.